Bio-Techne

TECH

Market cap $10.7B

Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MINNEAPOLIS , Dec. 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m.

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports complex assay configurations Strengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 compliance MINNEAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the expanded launch and first shipment of its next-generation Leo™ System, powered by Simple Western™ Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples.

Bio-Techne Corporation (TECH) Presents at 53rd Annual Nasdaq Investor Conference Transcript

Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

MINNEAPOLIS , Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 8th Annual Evercore Healthcare Conference 2025 December 2, 2025 8:20 AM EST Citi's 2025 Global Healthcare Conference December 3, 2025 3:15 PM EST 53rd Annual Nasdaq Investor Conference December 9, 2025 9:30 AM GMT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Bio-Techne Corporation ( TECH ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:30 AM EST Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Tycho Peterson Tycho Peterson Presentation Tycho Peterson Okay. Great. We're going to kick it off.

Bio-Techne Corporation ( TECH ) Stephens Annual Investment Conference 2025 November 18, 2025 9:00 AM EST Company Participants James Hippel - Executive VP of Finance & CFO William Geist - President of Protein Sciences Segment Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division [Audio Gap] Is intended to be more of a fireside chat, so I'll stop along the way and poll for any questions. So feel free to chime in as needed.

Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine MINNEAPOLIS and SEATTLE , Nov. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.